Efficiency of Intranasal Fentanyl in Patients with Breakthrough Cancer Pain in Daily Practice - Results of the German Non-Interventional Study with Instanyl® (GENISIS)
<p><strong>Objective: </strong>Breakthrough cancer pain (BTcP) affects 19-95% of cancer patients (dependent on the definition and methods used and the populations studied) and is associated with detrimental physical, psychological and social complications in affected individuals as...
Bewaard in:
Hoofdauteurs: | Michael A Ueberall (Auteur), Bernd-Oliver Maier (Auteur), Thomas Nolte (Auteur) |
---|---|
Formaat: | Boek |
Gepubliceerd in: |
Global Journal of Anesthesiology - Peertechz Publications,
2014-10-15.
|
Onderwerpen: | |
Online toegang: | Connect to this object online. |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Gelijkaardige items
-
Single-dose fentanyl sublingual spray for breakthrough cancer pain
door: Taylor DR
Gepubliceerd in: (2013) -
Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain
door: Darbà J, et al.
Gepubliceerd in: (2013) -
Intranasal (IN) COVID-19 vaccines - a breakthrough
door: Ramandeep Singh Gambhir, et al.
Gepubliceerd in: (2023) -
Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets
door: Jordi Guitart, et al.
Gepubliceerd in: (2019) -
Safety of nurse-directed triage intranasal fentanyl protocol for acute pain management in a European pediatric emergency department: A retrospective observational analysis
door: F. Romano, et al.
Gepubliceerd in: (2023)